Skip to main content

Table 1 Patient characteristics

From: Implementation of guidelines for metabolic syndrome control in kidney transplant recipients: results at a single center

  1994–1997 2008–2011 p value
Number of patients 74 238  
Sex    0.489a
 Male 66.20 % 61.80 %  
 Female 33.80 % 38.20 %  
ESRD etiology    <0.005b
 APCKD 4.84 % 12.44 %  
 Familial 11.29 % 15.79 %  
 Glomerular disease 53.23 % 37.32 %  
 DM 3.23 % 12.44 %  
 HTN 0.00 % 5.26 %  
 Other 27.42 % 16.75 %  
Creatinine at beginning of FU period (μmol/l) (mean) 134 128 0.314c
Weight at beginning of FU period (kg) (mean) 72.3 78 0.01c
Pre-transplant DM 2.8 % 16.9 % 0.002a
Cyclosporine treatment 90.5 % 29.0 % <0.001a
Last cyclosporine level (ng/mL) (mean) 139.3 63.3 <0.0001c
Tacrolimus treatment 0.0 % 60.9 % <0.001a
Last tacrolimus level (ng/mL) (mean) 5.5  
Place of transplant    <0.001a
 Israel 80.0 % 47.8 %  
 USA/Europe 6.7 % 11.4 %  
 Others 13.3 % 40.8 %  
Donor living/deceased    0.002a
 Deceased 50.8 % 29.6 %  
 Living 49.2 % 70.4 %  
Donor related 31.0 % 29.9 % 0.868a
Age at beginning of FU (mean) 43.15 ± 11.3 49.69 ± 13.6 0.001c
Years on dialysis (mean) 4.13 ± 4.9 2.88 ± 3.5 0.076c
Age at transplantation (mean) 38.57 ± 11.8 42.29 ± 14.4 0.026c
Years from transplantation (mean) 4.84 ± 3.8 7.15 ± 5.0 0.001c
  1. ADPKD adult polycystic kidney disease, DM diabetes mellitus, HTN hypertension, FU follow up
  2. aPearson Chi square
  3. bFisher’s exact test
  4. cT-test